Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

85 results about "Hedgehog signalling" patented technology

Pyridyl-Triazine Inhibitors of Hedgehog Signaling

The invention provides pyridyl-triazine derivatives to inhibit the hedgehog signaling pathway and the use of such compounds in the treatment of hyperproliferative diseases and angiogenisis mediated diseases.
Owner:CALIFORNIA CAPITAL EQUITY

RNA interference modulators of hedgehog signaling and uses thereof

The instant application relates to methods and reagents for modulating the Hedgehog signaling pathway using RNA interference technology (RNAi). The application provides potential targets of the Hedgehog RNAi, methods to identify additional Hedgehog signaling pathway components, methods to inhibit Hedgehog signaling targets using siRNA, and their uses in the treatment of a number of disease conditions.
Owner:CURIS INC +1

Pyridyl inhibitors of hedgehog signalling

The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
Owner:CURIS INC +1

Pyridyl inhibitors of hedgehog signalling

The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I:wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
Owner:GENENTECH INC +1

Modulators of hedgehog signaling pathways, compositions and uses related thereto

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. Such methods and reagents may also inhibit the hedgehog pathway in normal cells, e.g., where normal levels of hedgehog signalling are unwanted.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Pyrimidinamine and pyridinamine Hedgehog signal conduction inhibitors

The invention relates to pyrimidinamine and pyridinamine Hedgehog signal conduction inhibitors. The inhibitors are compounds with the structure represented by formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to a medicinal use of the above compounds as hedgehog signal conduction inhibitors.
Owner:HAINAN SIMCERE PHARMA CO LTD

Bicyclic heterocyclic amine Hedgehog signal pathway inhibitor

The invention relates to the field of biological medicine, and concretely relates to bicyclic heterocyclic amine compounds, and the compounds are a new Hedgehog inhibitor and pharmaceutically acceptable salts shown as a general formula (I). The compounds can be used as a Hedgehog signal conduction inhibitor applied to multiple medical applications.
Owner:HAINAN SIMCERE PHARMA CO LTD

Therapeutic use

Use of an inhibitor of a Hedgehog signalling pathway, or an inhibitor of a pathway which is a target of the Hedgehog signalling pathway in the preparation of a medicament for treatment of epithelial cell hyperplasia, fibrosis of tissue, inflammation, cancer or an immune disorder.
Owner:CELLDEX THERAPEUTICS LIMITED

Rubiaceae-type cyclopeptide taken as Hedgehog signal channel inhibitor as well as preparation method and application of rubiaceae-type cyclopeptide

The invention provides a rubiaceae-type cyclopeptide taken as a novel Hedgehog signal channel inhibitor as well as a preparation method and an application of the rubiaceae-type cyclopeptide in preparation of a medicine for treating and preventing relevant cancers activated by the abnormity of Hedgehog signal channels. The rubiaceae-type cyclopeptide is prepared by the condensation of one D-alpha-alanine, one L-alpha-alanine, three substituted N-methyl-L-alpha-tyrosines and one L-alpha-amino acid of another type via peptide bonds, wherein six amino acids are condensed into an eighteen-membered rings; and benzene rings between two adjacent tyrosines are connected via an oxygen bridge so as to form a fourteen-membered ring.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI +1

Bisamide Inhibitors of Hedgehog Signaling

The invention provides inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I:wherein ring A, ring B, R1, R2, R3, R4, R5, m and n are as defined herein.
Owner:GENENTECH INC +1

Composition and methods for modulating CNS activity

The present invention concerns the methods and compositions for treating depression and other behavioral and / or emotional disorders of the central nervous system by administering an agonist of hedgehog signaling. Other disorders amenable to treatment by the subject method include attention deficit hyperactive disorders, non-Alzheimer dementia, and various symptoms of memory loss. The present invention also concerns the methods and compositions for enhancing memory and / or cognitive functions, both in a patient suffering from ailment affecting these functions, and in a subject with no diagnosed deficit in memory or cognitive function. The methods and compositions of the present invention stimulate neurogenesis and differentiation, and enhance synaptic transmission of neurons.
Owner:CURIS INC

Compound as Hedgehog path inhibitor, medicine composition containing same and application thereof

The invention provides a compound of general formula I as an inhibitor and a preparation method thereof. The compound is used for inhibiting a Hedgehog signal path and can provide a new medicine for clinic effective cancer resistance. The invention also provides a medicine composition as an inhibitor, which contains the compound I as an effective ingredient and can be used for inhibiting the Hedgehog signal path so as to resist cancer. In addition, the invention also provides an application of the compound in the preparation of the medicine for inhibiting the Hedgehog signal path.
Owner:BEIJING HANMI PHARMA CO LTD

Hedgehog signaling promotes the formation of three dimensional cartilage matrices

The present invention provides methods and compositions for promoting the formation of three dimensional cartilage matrices. The present invention further provides methods of treating diseases and injuries involving cartilage and bone using the three dimensional cartilage matrices provided herein.
Owner:CURIS INC

Hedgehog signaling and cancer stem cells in hematopoietic cell malignancies

The present disclosure relates generally to methods of treating hematopoietic cell malignancy in a subject by administering to the subject a Hedgehog (Hh) pathway antagonist, such as a Smoothen (Smo) antagonist alone or in combination with an ABL-kinase antagonist. Specifically, the disclosure relates to a method of treating hematopoietic cell malignancy in a subject by administering the Hh pathway antagonist, such as the Smo antagonist cyclopamine, in combination with the ABL-kinase antagonist imatinib.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1

Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling

The invention provides isoquinoline, quinoline, and quinazoline derivatives to treat a variety of disorders, diseases and pathologic conditions, and more specifically to the use of isoquinoline, quinoline, and quinazoline derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds to the treatment of hyperproliferative diseases and pathologic angiogenesis.
Owner:NANTBIOSCI

In vitro pancreatic differentiation of pluripotent mammalian cells

This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (DE) medium comprising a TGFp ligand, fibroblast growth factor ( FGF), bone morphogenetic protein (BMP), a PI3K inhibitor and optionally a GSK3 β inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; FGF; retinoic acid; and a BMP inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising FGF, retinoic acid, a BMP inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising FGF. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells. These methods may be useful, for example, in producing pancreatic cells for therapy or disease modelling.
Owner:CAMBRIDGE ENTERPRISE LTD

Hedgehog antagonists having zinc binding moieties

The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.
Owner:CURIS INC +1

Targeting nucleic acid drug as well as preparation method and application thereof

The invention provides a targeting nucleic acid drug as well as a preparation method and an application thereof. The targeting nucleic acid drug comprises an amino lipid-hyaluronic acid conjugate, a cationic liposome and a complex containing protamine, chondroitin sulfate and a nucleic acid drug, the amino lipid part of the amino lipid-hyaluronic acid conjugate is combined with the cationic liposome, and the cationic liposome wraps the complex. The targeting nucleic acid drug inhibits self-renewal and migration invasion of cancer cells by specifically blocking a Hedgehog signal transduction pathway of cell self-proliferation and differentiation, induces cell apoptosis, and can effectively inhibit recurrence of tumors.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI

Oxysterols and hedgehog signaling

Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit Hedgehog signaling. Also described herein are methods for using such Hedgehog signaling inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of Hedgehog signaling.
Owner:MAX BIOPHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products